Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 134 entries
Sorted by: Best Match Show Resources per page
Idiopathic pulmonary fibrosis.

Nature reviews. Disease primers

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.
PMID: 29052582
Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It is associated with increasing cough and dyspnoea and impaired quality of life. IPF affects...

Cite
Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074doi: 10.1038/nrdp.2017.74.
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017). Idiopathic pulmonary fibrosis. Nature reviews. Disease primers, 317074. https://doi.org/10.1038/nrdp.2017.74
Martinez, Fernando J, et al. "Idiopathic pulmonary fibrosis." Nature reviews. Disease primers vol. 3 (2017): 17074. doi: https://doi.org/10.1038/nrdp.2017.74
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. PMID: 29052582.
Copy Download .nbib Format: NLM
Novel drug targets for idiopathic pulmonary fibrosis.

Expert review of respiratory medicine

Sgalla G, Cocconcelli E, Tonelli R, Richeldi L.
PMID: 26854382
Expert Rev Respir Med. 2016 Apr;10(4):393-405. doi: 10.1586/17476348.2016.1152186. Epub 2016 Feb 26.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disorder of unknown cause with a highly variable and unpredictable clinical course. The advances made in deciphering IPF pathobiology over the last decades have led to the approval of two...

Cite
Sgalla G, Cocconcelli E, Tonelli R, et al. Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016;10(4):393-405doi: 10.1586/17476348.2016.1152186.
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016). Novel drug targets for idiopathic pulmonary fibrosis. Expert review of respiratory medicine, 10(4), 393-405. https://doi.org/10.1586/17476348.2016.1152186
Sgalla, Giacomo, et al. "Novel drug targets for idiopathic pulmonary fibrosis." Expert review of respiratory medicine vol. 10,4 (2016): 393-405. doi: https://doi.org/10.1586/17476348.2016.1152186
Sgalla G, Cocconcelli E, Tonelli R, Richeldi L. Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016 Apr;10(4):393-405. doi: 10.1586/17476348.2016.1152186. Epub 2016 Feb 26. PMID: 26854382.
Copy Download .nbib Format: NLM
Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21.

Frontiers in neuroscience

Farioli-Vecchioli S, Micheli L, Leonardi L, Ceccarelli M, Cavallaro S, Tirone F.
PMID: 23355800
Front Neurosci. 2013 Jan 24;6:198. doi: 10.3389/fnins.2012.00198. eCollection 2012.

No abstract available.

Cite
Farioli-Vecchioli S, Micheli L, Leonardi L, et al. Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21. Front Neurosci. 2013;6:198doi: 10.3389/fnins.2012.00198.
Farioli-Vecchioli, S., Micheli, L., Leonardi, L., Ceccarelli, M., Cavallaro, S., & Tirone, F. (2012). Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21. Frontiers in neuroscience, 6198. https://doi.org/10.3389/fnins.2012.00198
Farioli-Vecchioli, Stefano, et al. "Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21." Frontiers in neuroscience vol. 6 (2012): 198. doi: https://doi.org/10.3389/fnins.2012.00198
Farioli-Vecchioli S, Micheli L, Leonardi L, Ceccarelli M, Cavallaro S, Tirone F. Medulloblastoma or not? Crucial role in tumorigenesis of the timing of migration of cerebellar granule precursor cells, regulated by Nos2 and Tis21. Front Neurosci. 2013 Jan 24;6:198. doi: 10.3389/fnins.2012.00198. eCollection 2012. PMID: 23355800; PMCID: PMC3553397.
Copy Download .nbib Format: NLM
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

American journal of respiratory and critical care medicine

Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D.
PMID: 24032382
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.

BACKGROUND: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology and diagnostic criteria. In addition, the historical "gold standard" of histologic diagnosis was replaced by...

Cite
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48doi: 10.1164/rccm.201308-1483ST.
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., Behr, J., Bouros, D., Brown, K. K., Colby, T. V., Collard, H. R., Cordeiro, C. R., Cottin, V., Crestani, B., Drent, M., Dudden, R. F., Egan, J., Flaherty, K., Hogaboam, C., Inoue, Y., Johkoh, T., Kim, D. S., Kitaichi, M., Loyd, J., Martinez, F. J., Myers, J., Protzko, S., Raghu, G., Richeldi, L., Sverzellati, N., Swigris, J., Valeyre, D. (2013). An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American journal of respiratory and critical care medicine, 188(6), 733-48. https://doi.org/10.1164/rccm.201308-1483ST
Travis, William D, et al. "An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias." American journal of respiratory and critical care medicine vol. 188,6 (2013): 733-48. doi: https://doi.org/10.1164/rccm.201308-1483ST
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST. PMID: 24032382; PMCID: PMC5803655.
Copy Download .nbib Format: NLM
Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.

New microbes and new infections

Bedini A, Garlassi E, Stentarelli C, Petrella S, Meacci M, Meccugni B, Meschiari M, Franceschini E, Cerri S, Brasacchio A, Rumpianesi F, Richeldi L, Mussini C.
PMID: 27222718
New Microbes New Infect. 2016 Apr 07;12:45-51. doi: 10.1016/j.nmni.2016.03.010. eCollection 2016 Jul.

The optimal treatment for latent tuberculosis infection (LTBI) in subjects exposed to multidrug-resistant (MDR) tuberculosis (TB) remains unclear, and the change in response of the QuantiFERON-TB Gold In-Tube (QTB-IT) test during and after treatment is unknown. Between May 2010...

Cite
Bedini A, Garlassi E, Stentarelli C, et al. Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New Microbes New Infect. 2016;12:45-51doi: 10.1016/j.nmni.2016.03.010.
Bedini, A., Garlassi, E., Stentarelli, C., Petrella, S., Meacci, M., Meccugni, B., Meschiari, M., Franceschini, E., Cerri, S., Brasacchio, A., Rumpianesi, F., Richeldi, L., & Mussini, C. (2016). Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New microbes and new infections, 1245-51. https://doi.org/10.1016/j.nmni.2016.03.010
Bedini, A, et al. "Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays." New microbes and new infections vol. 12 (2016): 45-51. doi: https://doi.org/10.1016/j.nmni.2016.03.010
Bedini A, Garlassi E, Stentarelli C, Petrella S, Meacci M, Meccugni B, Meschiari M, Franceschini E, Cerri S, Brasacchio A, Rumpianesi F, Richeldi L, Mussini C. Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New Microbes New Infect. 2016 Apr 07;12:45-51. doi: 10.1016/j.nmni.2016.03.010. eCollection 2016 Jul. PMID: 27222718; PMCID: PMC4872473.
Copy Download .nbib Format: NLM
The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

ERJ open research

Richeldi L, Launders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR.
PMID: 30949489
ERJ Open Res. 2019 Apr 01;5(2). doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr.

Multidisciplinary team (MDT) diagnosis of interstitial lung disease (ILD) has been proposed as a gold standard, but there are no formal recommendations for MDT process or composition and limited knowledge regarding prevalence in routine practice. We performed a systematic...

Cite
Richeldi L, Launders N, Martinez F, et al. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res. 2019;5(2)doi: 10.1183/23120541.00209-2018.
Richeldi, L., Launders, N., Martinez, F., Walsh, S. L. F., Myers, J., Wang, B., Jones, M., Chisholm, A., & Flaherty, K. R. (2019). The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ open research, 5(2), . https://doi.org/10.1183/23120541.00209-2018
Richeldi, Luca, et al. "The characterisation of interstitial lung disease multidisciplinary team meetings: a global study." ERJ open research vol. 5,2 (2019). doi: https://doi.org/10.1183/23120541.00209-2018
Richeldi L, Launders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res. 2019 Apr 01;5(2). doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr. PMID: 30949489; PMCID: PMC6441673.
Copy Download .nbib Format: NLM
Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability.

Frontiers in neurology

Giorgio A, Zhang J, Stromillo ML, Rossi F, Battaglini M, Nichelli L, Mortilla M, Portaccio E, Hakiki B, Amato MP, De Stefano N.
PMID: 29184534
Front Neurol. 2017 Nov 14;8:608. doi: 10.3389/fneur.2017.00608. eCollection 2017.

Pediatric-onset multiple sclerosis (POMS) may represent a model of vulnerability to damage occurring during a period of active maturation of the human brain. Whereas adaptive mechanisms seem to take place in the POMS brain in the short-medium term, natural...

Cite
Giorgio A, Zhang J, Stromillo ML, et al. Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Front Neurol. 2017;8:608doi: 10.3389/fneur.2017.00608.
Giorgio, A., Zhang, J., Stromillo, M. L., Rossi, F., Battaglini, M., Nichelli, L., Mortilla, M., Portaccio, E., Hakiki, B., Amato, M. P., & De Stefano, N. (2017). Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in neurology, 8608. https://doi.org/10.3389/fneur.2017.00608
Giorgio, Antonio, et al. "Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability." Frontiers in neurology vol. 8 (2017): 608. doi: https://doi.org/10.3389/fneur.2017.00608
Giorgio A, Zhang J, Stromillo ML, Rossi F, Battaglini M, Nichelli L, Mortilla M, Portaccio E, Hakiki B, Amato MP, De Stefano N. Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Front Neurol. 2017 Nov 14;8:608. doi: 10.3389/fneur.2017.00608. eCollection 2017. PMID: 29184534; PMCID: PMC5694464.
Copy Download .nbib Format: NLM
Reply to Moodley and to Ravaglia et al.

American journal of respiratory and critical care medicine

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Wilson K.
PMID: 30566844
Am J Respir Crit Care Med. 2019 Mar 01;199(5):667-669. doi: 10.1164/rccm.201810-2006LE.

No abstract available.

Cite
Raghu G, Remy-Jardin M, Myers JL, et al. Reply to Moodley and to Ravaglia et al. Am J Respir Crit Care Med. 2019;199(5):667-669doi: 10.1164/rccm.201810-2006LE.
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., & Wilson, K. (2019). Reply to Moodley and to Ravaglia et al. American journal of respiratory and critical care medicine, 199(5), 667-669. https://doi.org/10.1164/rccm.201810-2006LE
Raghu, Ganesh, et al. "Reply to Moodley and to Ravaglia et al." American journal of respiratory and critical care medicine vol. 199,5 (2019): 667-669. doi: https://doi.org/10.1164/rccm.201810-2006LE
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Wilson K. Reply to Moodley and to Ravaglia et al. Am J Respir Crit Care Med. 2019 Mar 01;199(5):667-669. doi: 10.1164/rccm.201810-2006LE. PMID: 30566844.
Copy Download .nbib Format: NLM
Ultramicronized .

Frontiers in pharmacology

Di Cesare Mannelli L, Micheli L, Lucarini E, Ghelardini C.
PMID: 29910726
Front Pharmacol. 2018 Jun 01;9:473. doi: 10.3389/fphar.2018.00473. eCollection 2018.

The facilitation of opioid medication is eliciting a nemetic problem since increasing overdose deaths involve prescription of opioid pain relievers. Chronic painful diseases require higher doses of opioids, progressively with the development of tolerance to the antinociceptive effect. Novel...

Cite
Di Cesare Mannelli L, Micheli L, Lucarini E, et al. Ultramicronized . Front Pharmacol. 2018;9:473doi: 10.3389/fphar.2018.00473.
Di Cesare Mannelli, L., Micheli, L., Lucarini, E., & Ghelardini, C. (2018). Ultramicronized . Frontiers in pharmacology, 9473. https://doi.org/10.3389/fphar.2018.00473
Di Cesare Mannelli, Lorenzo, et al. "Ultramicronized ." Frontiers in pharmacology vol. 9 (2018): 473. doi: https://doi.org/10.3389/fphar.2018.00473
Di Cesare Mannelli L, Micheli L, Lucarini E, Ghelardini C. Ultramicronized . Front Pharmacol. 2018 Jun 01;9:473. doi: 10.3389/fphar.2018.00473. eCollection 2018. PMID: 29910726; PMCID: PMC5992817.
Copy Download .nbib Format: NLM
A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement.

Respiratory medicine

Blasi F, Di Pasquale M, Gramegna A, Viale P, Iacobello C, Gori A, Tumbarello M, Esposito S, Richeldi L, Bassetti M.
PMID: 34788734
Respir Med. 2021 Dec;190:106674. doi: 10.1016/j.rmed.2021.106674. Epub 2021 Nov 01.

Influenza and pneumococcal disease represent a well-known burden on healthcare systems worldwide, as well as they still have an attributed morbidity and mortality, especially in elderly individuals and vulnerable populations. In the context of the ongoing pandemic of COVID-19,...

Cite
Blasi F, Di Pasquale M, Gramegna A, et al. A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respir Med. 2021;190:106674doi: 10.1016/j.rmed.2021.106674.
Blasi, F., Di Pasquale, M., Gramegna, A., Viale, P., Iacobello, C., Gori, A., Tumbarello, M., Esposito, S., Richeldi, L., & Bassetti, M. (2021). A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respiratory medicine, 190106674. https://doi.org/10.1016/j.rmed.2021.106674
Blasi, Francesco, et al. "A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement." Respiratory medicine vol. 190 (2021): 106674. doi: https://doi.org/10.1016/j.rmed.2021.106674
Blasi F, Di Pasquale M, Gramegna A, Viale P, Iacobello C, Gori A, Tumbarello M, Esposito S, Richeldi L, Bassetti M. A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respir Med. 2021 Dec;190:106674. doi: 10.1016/j.rmed.2021.106674. Epub 2021 Nov 01. PMID: 34788734; PMCID: PMC8559458.
Copy Download .nbib Format: NLM
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't.

Annals of translational medicine

Sgalla G, Mari PV, Richeldi L.
PMID: 33437814
Ann Transl Med. 2020 Dec;8(23):1615. doi: 10.21037/atm-20-3243.

No abstract available.

Cite
Sgalla G, Mari PV, Richeldi L. Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't. Ann Transl Med. 2020;8(23):1615doi: 10.21037/atm-20-3243.
Sgalla, G., Mari, P. V., & Richeldi, L. (2020). Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't. Annals of translational medicine, 8(23), 1615. https://doi.org/10.21037/atm-20-3243
Sgalla, Giacomo, et al. "Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't." Annals of translational medicine vol. 8,23 (2020): 1615. doi: https://doi.org/10.21037/atm-20-3243
Sgalla G, Mari PV, Richeldi L. Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't. Ann Transl Med. 2020 Dec;8(23):1615. doi: 10.21037/atm-20-3243. PMID: 33437814; PMCID: PMC7791202.
Copy Download .nbib Format: NLM
VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody.

Journal of experimental & clinical cancer research : CR

Micheli L, Parisio C, Lucarini E, Vona A, Toti A, Pacini A, Mello T, Boccella S, Ricciardi F, Maione S, Graziani G, Lacal PM, Failli P, Ghelardini C, Di Cesare Mannelli L.
PMID: 34649573
J Exp Clin Cancer Res. 2021 Oct 14;40(1):320. doi: 10.1186/s13046-021-02127-x.

BACKGROUND: Neuropathic pain is a clinically relevant adverse effect of several anticancer drugs that markedly impairs patients' quality of life and frequently leads to dose reduction or therapy discontinuation. The poor knowledge about the mechanisms involved in neuropathy development...

Cite
Micheli L, Parisio C, Lucarini E, et al. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res. 2021;40(1):320doi: 10.1186/s13046-021-02127-x.
Micheli, L., Parisio, C., Lucarini, E., Vona, A., Toti, A., Pacini, A., Mello, T., Boccella, S., Ricciardi, F., Maione, S., Graziani, G., Lacal, P. M., Failli, P., Ghelardini, C., & Di Cesare Mannelli, L. (2021). VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. Journal of experimental & clinical cancer research : CR, 40(1), 320. https://doi.org/10.1186/s13046-021-02127-x
Micheli, Laura, et al. "VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody." Journal of experimental & clinical cancer research : CR vol. 40,1 (2021): 320. doi: https://doi.org/10.1186/s13046-021-02127-x
Micheli L, Parisio C, Lucarini E, Vona A, Toti A, Pacini A, Mello T, Boccella S, Ricciardi F, Maione S, Graziani G, Lacal PM, Failli P, Ghelardini C, Di Cesare Mannelli L. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res. 2021 Oct 14;40(1):320. doi: 10.1186/s13046-021-02127-x. PMID: 34649573; PMCID: PMC8515680.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 134 entries